[quick news] on July 20, 2018, graphene "three proofing" coating technology was successfully developed to fill the gap in China

The successful development of graphene "three proofing" coating technology fills the gap in China A kind of graphene "three proofing" coating technology, which can prevent high temperature and humidity, salt fog corrosion and mould, has been developed in Qinhuangdao Economic and Technological Development Zone, Hebei Province The technology can be applied to the protection of high temperature parts of ship gas turbine, aerospace engine, salt fog and marine biological corrosion, etc., filling the market gap of high temperature coating technology in heavy salt fog area Http://news.scienceet.cn/htmlnews/2018/7/415726.shtm Beijing universities will carry out "discipline co construction" in 28 disciplines 12 universities under the central and subordinate departments of Beijing and 20 universities under the municipal government signed the "discipline co construction plan of Beijing universities" on the 18th, which will carry out "discipline co construction" in 28 disciplines It is understood that the contracted universities will further open the discipline chain, realize resource sharing, form cluster effect and improve discipline construction level through teacher exchange, scientific research cooperation, joint training and other ways Http://www.xinhuanet.com/2018-07/19/c_.htm the success of the new engine test will greatly improve the transport capacity of China's launch vehicles The reporter recently learned from the sixth Academy of Aerospace Science and technology group that the first high-powered and high-performance high-altitude liquid oxygen kerosene engine developed by the academy has achieved a complete success in the first hot commissioning of the whole engine Experts said that the success of this test is of great significance to greatly improve the launch capacity of China's new generation of launch vehicles and broaden the rocket type spectrum, adding new impetus to the further development of China's aerospace industry Http://www.xinhuanet.com/politics/2018-07/19/c_.htm for the benefit of influenza patients, Roche's heavyweight new drug has made three phases of positive progress recently, Genentech, a subsidiary of Roche, a global pharmaceutical giant, announced that capstone-2, a three-phase study to evaluate the efficacy of balxavir marboxil, a heavyweight new influenza drug, in people with high risk of influenza complications Reached the main destination If approved by FDA, baloxavir marboxil will become the first single dose oral antiviral drug, and the first drug with a new mechanism of influenza treatment in 20 years Https://www.gene.com/media/press-releases/14735/2018-07-16/phase-iii-capstone-2-study-shown-that-b new drug of Janssen was approved by FDA Recently, Janssen, a subsidiary of Johnson & Johnson, a pharmaceutical giant, announced that symtuza, a new drug of the company to treat HIV infection, has been approved by FDA Symtuza is a four in one fixed dose single-chip compound preparation with darunavir as the core It has the characteristics of high resistance barrier and good tolerance Moreover, patients only need to take one tablet once a day, one at a time, which reduces the burden of taking medicine for HIV infected people, so as to help improve the compliance of patients https://www.janssen.com/janssen-announces-us-fda-approval-symtuza-dcftaf-first-and-only-complete-darunavir-based-single-0